In the 4/5/2005 issue of Cell-Based Assay News, the article “Euroscreen Wins Addional Aequorin Screening Patent; Seeks to Expand Instrument Partners” contained factual errors. EuroScreen has approximately 50 employees in R&D, not 15 as stated in the article. In addition, EuroScreen uses the FMAT8100 high-throughput screening system, which is currently available from Applied Biosystems, and not the discontinued FMAT as stated.
Correction: Apr 12, 2005
Apr 12, 2005